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In Brief
Comparative gene identification 58 (CGI-
58) is thought to regulate triacylglycerol
mobilization by stimulating the enzymatic
activity of adipose triglyceride lipase
(ATGL). Lord et al. now show that CGI-58
regulates hepatic triacylglycerol turnover
and inflammation in the genetic absence
of ATGL, demonstrating an ATGL-
independent role for CGI-58 in mouse
liver.
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Adipose triglyceride lipase (ATGL) and comparative
gene identification 58 (CGI-58) are critical regulators
of triacylglycerol (TAG) turnover. CGI-58 is thought
to regulate TAGmobilization by stimulating the enzy-
matic activity of ATGL. However, it is not known
whether this coactivation function of CGI-58 occurs
in vivo. Moreover, the phenotype of human CGI-58
mutations suggests ATGL-independent functions.
Through direct comparison of mice with single or
double deficiency of CGI-58 and ATGL, we show
here that CGI-58 knockdown causes hepatic stea-
tosis in both the presence and absence of ATGL.
CGI-58 also regulates hepatic diacylglycerol (DAG)
and inflammation in an ATGL-independent manner.
Interestingly, ATGL deficiency, but not CGI-58 defi-
ciency, results in suppression of the hepatic and
adipose de novo lipogenic program. Collectively,
these findings show that CGI-58 regulates hepatic
neutral lipid storage and inflammation in the genetic
absence of ATGL, demonstrating that mechanisms
driving TAG lipolysis in hepatocytes differ signifi-
cantly from those in adipocytes.
INTRODUCTION
The mobilization of triacylglycerol (TAG) from cellular lipid drop-
lets has become an area of intense research and has been linked
to a large number of physiological processes, including energy
balance, signaling, gene transcription, and cell-cycle progres-
sion (Zechner et al., 2012; Greenberg et al., 2011). Recently, a
rare autosomal-recessive disorder of TAG accumulation known
as neutral lipid storage disease (NLSD) was linked to mutations
in either CGI-58 or ATGL (Lefe`vre et al., 2001; Fischer et al.,This is an open access article under the CC BY-N2007), linking these proteins to TAG storage in humans. ATGL
(adipose triglyceride lipase, also known as PNPLA2 or desnutrin)
functions as a critical lipase with specificity toward TAG (Zim-
mermann et al., 2004). CGI-58 has been shown to indirectly pro-
mote TAG turnover by serving as a co-activator of ATGL, and this
function is lost with CGI-58 mutations that cause NLSD (Lass
et al., 2006). Furthermore, the addition of purified CGI-58 can
increase TAG hydrolase activity in white adipose tissue lysates
from wild-type mice, but not from mice lacking ATGL, indicating
specificity for ATGL and suggesting that endogenous levels of
CGI-58 limit maximal lipolysis (Schweiger et al., 2006).
Although loss of ATGL co-activation is a possible explanation
for TAG accumulation in NLSD patients with CGI-58 mutations,
there is also strong evidence that CGI-58 has ATGL-independent
functions (Lord and Brown, 2012). For example, CGI-58 muta-
tions always cause ichthyosis and frequently result in severe
fatty liver disease and neurological defects, whereas ATGL mu-
tations primarily cause myopathies and rarely result in fatty liver
disease or ichthyosis (Lord and Brown, 2012). The metabolic
phenotypes of CGI-58 and ATGL deficiency in mice also differ
significantly (Haemmerle et al., 2006, 2011; Radner et al.,
2010; Schreiber et al., 2015; Ahmadian et al., 2011; Brown
et al., 2010; Lord et al., 2012; Cantley et al., 2013). For instance,
global CGI-58 knockout mice die shortly after birth due to a skin
barrier defect (Radner et al., 2010), while ATGL global knockout
mice survive for several months before ultimately succumbing
to a lethal cardiomyopathy (Haemmerle et al., 2006). Further-
more, hepatocyte-specific (Guo et al., 2013; Hoy et al., 2011)
or macrophage-specific (Goeritzer et al., 2014; Lammers et al.,
2011; Aflaki et al., 2011a, 2011b; Miao et al., 2014) deletion of
CGI-58 or ATGL results in divergent effects on inflammatory
processes in the liver and artery wall in the context of atheroscle-
rosis. Adipose-selective overexpression of CGI-58 in mice does
not increase basal or hormone-stimulated lipolysis, calling into
question the physiological importance of CGI-58 as a rate-
limiting co-activator of ATGL (Caviglia et al., 2011). To determine
whether ATGL-mediated lipolysis actually requires CGI-58 underCell Reports 16, 939–949, July 26, 2016 ª 2016 The Author(s). 939
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. CGI-58 Regulates Hepatic Triacyl-
glycerol Storage via a Mechanism Distinct
from ATGL Co-activation
At 4–6 weeks of age, male wild-type or ATGLKO
mice were treated with either a non-targeting
control ASO (WT, ATGLKO) or an ASO targeting
CGI-58 (CGI-58D, ATGLKO/CGI-58D) in conjunc-
tion with high-fat diet feeding for 6–8 weeks.
(A) RelativemRNA expression of CGI-58 and ATGL
in whole liver.
(B) Liver weight normalized to tibia length.
(C) Total TAG hydrolase activity in cytosolic ex-
tracts of whole liver.
(D) Representative liver sections stained with H&E;
scale bar represents 75 mm.
(E) Hepatic triacylglycerol (TAG) levels.
(F) Hepatic diacylglycerol (DAG) levels.
Data represent the mean ± SEM from three to
seven mice per group, and values not sharing a
common superscript differ significantly (p < 0.05).physiological conditions and to directly test whether CGI-58 has
any ATGL-independent functions, we generated mouse models
with single or double deficiency of CGI-58 and ATGL. This could
not be achieved through breeding, because CGI-58 global
knockout mice die at birth due to a skin barrier defect (Radner
et al., 2010). Therefore, we used second-generation antisense
oligonucleotides (ASOs), which selectively target liver and adi-
pose tissue, to deplete CGI-58 in either ATGL global knockout
mice (ATGLKO) or wild-type littermates. As a result, we were
able to directly compare wild-type (WT), CGI-58 single-deficient
(CGI-58D), ATGL single-deficient (ATGLKO), and double-deficient
(ATGLKO/CGI-58D) mice. These mousemodels were used to test
the co-activation hypothesis in vivo.
RESULTS
CGI-58 Regulates Hepatic TAG and Diacylglycerol
Storage via a Mechanism Distinct from ATGL
Co-activation
CGI-58 expression in the liver was reduced by over 90% with
CGI-58 ASO treatment, and ATGL global knockout mice had
expected reductions in ATGL mRNA levels (Figure 1A). ATGL
deficiency alone did not change liver weight compared to WT
mice, but CGI-58 knockdown resulted in hepatomegaly in both
the presence and absence of ATGL (Figure 1B). Compared to
WT mice, TAG hydrolase activity in liver was decreased by
40% in CGI-58D mice and 60% in ATGLKO mice, with no further
decrease in ATGLKO/CGI-58D mice (Figure 1C), indicating both
CGI-58 and ATGL regulated TAG turnover in the liver. Liver
histology revealed striking steatosis in ATGLKO/CGI-58D mice940 Cell Reports 16, 939–949, July 26, 2016compared to CGI-58D mice and ATGLKO
mice (Figure 1D). Compared to WT
mice, hepatic TAG levels were on average
3.5-fold higher in CGI-58D mice and
3-fold higher in ATGLKO mice (Figure 1E).
Remarkably, ATGLKO/CGI-58D mice had
11.5-fold higher TAG, indicating an addi-
tive effect of doubledeficiency (Figure1E).Interestingly, ATGL and CGI-58 exert reciprocal effects on
hepatic diacylglycerol (DAG) levels. ATGL single deficiency
resulted in reduced levels of hepatic DAG, while CGI-58 knock-
down increased hepatic DAG levels both in the genetic presence
or absence of ATGL (Figure 1F). Therefore, CGI-58 knockdown
causes hepatomegaly and hepatic steatosis through a mecha-
nism separate from ATGL activity.
Divergent Control of Hepatic Inflammation and
Lipogenesis by CGI-58 and ATGL
Based on our previous findings that CGI-58 regulates systemic
inflammation (Lord et al., 2012), we investigated whether hepatic
inflammation differed between CGI-58 and ATGL deficiency.
CGI-58 knockdown, but not ATGL knockout, was associated
with higher hepatic expression of TH1-skewed macrophage
markers such as F4/80 and tumor necrosis factor alpha (TNF-a)
(Figure 2A). Likewise, increased transforming growth factor b
(TGF-b) expression (Figure 2B) suggested progression to non-
alcoholic steatohepatitis (NASH). Furthermore, ATGLKO/CGI-58D
mice had significantly higher expression of a-SMA (Figure 2A), a
marker of hepatic stellate cell activation. Collectively, these data
demonstrate that CGI-58 regulates hepatic inflammation via an
ATGL-independent mechanism.
Given that de novo lipogenesis is a major determinant of
hepatic DAG and TAG levels (Cohen et al., 2011), we set out to
determine whether lipogenic enzyme expression was altered
by CGI-58 or ATGL deficiency. Interestingly, the expression of
enzymes involved in de novo lipogenesis including acetyl-CoA
carboxylase (ACC1), fatty acid synthase (FAS), ATP-citrate lyase
(ATP-CL), and acetyl-CoA synthetase (AceCS1) were repressed
Figure 2. Divergent Control of Hepatic Inflammation and Lipo-
genesis by CGI-58 and ATGL
At 4–6 weeks of age, male wild-type or ATGLKO mice were treated with either
a non-targeting control ASO (WT, ATGLKO) or an ASO targeting CGI-58 (CGI-
58D, ATGLKO/CGI-58D) in conjunction with high fat diet feeding for 6 weeks.
(A) Inflammatory gene expression in whole liver was quantified by qPCR.
(B) Western blotting for lipogenic proteins in whole liver.
(C) Densitometric quantification of lipogenic protein expression in whole liver.
Abbreviations:a-Sma,a smoothmuscle actin;ACC1, acetyl-CoAcarboxylase1;
AceCS1, Acetyl-CoA synthetase 1; ATP-CL, ATP-citrate lyase; FAS, fatty acid
synthase; F4/80, EGF-like module-containing mucin-like hormone receptor-
like 1; Tgf-b, transforming growth factor b; Tnf-a, tumor necrosis factor a. Data
represent the mean + SEM of 3–5 mice per group; *significantly different WT
group (p < 0.05).by ATGL deficiency, yet not affected by CGI-58 ASO treatment
(Figures 2B and 2C). These data suggest that blocking TAG turn-
over via ATGL deficiency results in a compensatory decrease inthe expression of proteins involved in de novo lipogenesis
through an unknown mechanism, but this feedback regulation
is not apparent when CGI-58-driven TAG hydrolysis is limited.
Hepatic Expression of Key TAG Lipases Are Reduced in
CGI-58 and ATGL Loss-of-Function Mice
Given that we saw an additive effect of CGI-58 and ATGL defi-
ciency on hepatic TAG accumulation (Figures 1D and 1E), we
interrogatedwhether the expression of several other TAG lipases
known to regulate hepatic TAG turnover. To our surprise, the
protein levels of the hepatic TAG hydrolases of the carboxyles-
terase family (Ces1g/Es-X and Ces1d/TGH) were markedly
reduced, especially in mice lacking ATGL (Figures 3A–3C). Like-
wise, the mRNA levels of Ces1g/Es-X and Ces1d/TGH were
significantly lower in ATGL null mice (Figures 3D and 3E) These
data indicate that secondary alterations in hepatic lipase expres-
sion may contribute in part to the steatosis seen in ATGLKO
and double-deficient mice. Given that previous reports have
demonstrated that ATGLKO mice have defective activation of
the nuclear hormone receptor peroxisome proliferator acti-
vated-receptor a (PPARa) (Haemmerle et al., 2011), we interro-
gated whether CGI-58 likewise regulates PPARa activation and
whether this underlies the altered expression of Ces1g/Es-X
and Ces1d/TGH. To accomplish this, we provided the exoge-
nous PPARa agonist WY-14643 to chow-fed CGI-58 ASO-
treated mice (Figure 3F–3I). In agreement with our previous
work showing PPARa target gene expression is suppressed in
CGI-58 ASO-treated mice (Brown et al., 2010), the canonical
PPARa target gene Cyp4a10 was lower in CGI-58 ASO-treated
mice yet rescued back to control levels with WY-14643 adminis-
tration (Figure 3F). Importantly, CGI-58 ASO-driven hepatic TAG
accumulation was significantly blunted by WY-14643 treatment
(Figure 3G). Interestingly, mRNA expression of both Ces1g/
Es-X and Ces1d/TGH were stimulated by WY-14643 in control
ASO-treated mice (Figures 3H and 3I), indicating PPARa respon-
siveness. Furthermore, Ces1d/TGH was significantly reduced in
chow-fed CGI-58 ASO treated mice but rescued back to control
levels with WY-14643 treatment (Figure 3I). Collectively, these
data suggest that PPARa activation is blunted with both ATGL
(Haemmerle et al., 2011) and CGI-58 (Brown et al., 2010) defi-
ciency, which has the potential to impact fatty acid oxidation
(Haemmerle et al., 2011; Brown et al., 2007) and the expression
of TAG lipases (Figures 3H and 3I).
CGI-58 Knockdown in White Adipose Tissue Limits
ATGL-Mediated Lipolysis
Much like the liver (Figure 1A), we achieved expected reductions
of CGI-58 and ATGL also inWAT. Compared to normal activity in
WT mice, TAG hydrolase activity was significantly decreased by
33% in CGI-58D mice and 55% in ATGLKO mice (Figure 4B).
However, double deficiency in ATGLKO/CGI-58D mice did not
further decrease TAG hydrolase activity compared to ATGLKO
mice (Figure 4B). To test whether CGI-58 knockdown would
limit stimulated lipolysis in vivo, we measured plasma glycerol
and non-esterified fatty acids (NEFAs) in mice treated with
either saline or a b3-adrenergic receptor agonist (CL-316,243).
Stimulated lipolysis was significantly blunted in CGI-58D mice
compared to WT mice but was not further decreased inCell Reports 16, 939–949, July 26, 2016 941
Figure 3. Hepatic Expression of Key TAG Lipases Are Reduced in
CGI-58 and ATGL Loss-of-FunctionMice, which Can BeReversed by
Provision of an Exogenous PPARa Agonist
For (A)–(E), male wild-type or ATGLKO mice were treated with either
a non-targeting control ASO (WT, ATGLKO) or an ASO targeting CGI-58
942 Cell Reports 16, 939–949, July 26, 2016ATGLKO/CGI-58D mice compared to ATGLKO mice (Figure 4C).
Likewise, stimulated lipolysis in CGI-58D adipose explants was
significantly lower compared to WT explants, but lipolysis in
ATGLKO/CGI-58D explants did not differ from ATGLKO explants
(Figure 4D). These data support the model, suggesting that the
maximal stimulation of ATGL-mediated lipolysis in WAT requires
CGI-58 expression and that CGI-58 is a specific co-activator of
ATGL in WAT under physiological conditions.
CGI-58 or ATGL Deficiency Attenuates High-Fat-Diet-
Induced Obesity through Distinct Mechanisms
Given the blunted lipolysis in mice lacking CGI-58 and ATGL,
we examined adiposity and energy balance in these mice in
response to high-fat diet (HFD; 45%). In agreement with previous
studies (Haemmerle et al., 2006; Kienesberger et al., 2009),
we observed mildly elevated body weight in ATGLKO mice main-
tained on chow diet (Figure 5A). However, global ATGL defi-
ciency unexpectedly reduced body weight in HFD-fed mice
(Figure 5B). As previously described (Brown et al., 2010; Cantley
et al., 2013), CGI-58 knockdown also reduced body weight in
HFD-fed mice (Figure 5B). In addition, CGI-58 and ATGL defi-
ciency reduced epididymal fat pad weight (Figure 5C) and
adipocyte size in HFD-fed mice (Figure 5D). We recently showed
that this paradoxical lean phenotype in high-fat-fed ATGLKO
mice is driven in large part to compensatory downregulation of
de novo lipogenesis in WAT (Schreiber et al., 2015). In contrast
to significantly reduced expression in high-fat-fed ATGLKO
mice, CGI-58 knockdown did not alter WAT lipogenic gene
expression (Figure 5F). In contrast to the liver (Figures 3A–3E),
ATGL or CGI-58 deficiency did not result in alterations of lipase
gene expression (Figure 5G). Rather than reducingWAT lipogen-
esis, CGI-58 knockdown appeared to attenuate diet-induced
obesity by increasing energy expenditure (Figure 5E). In contrast,
energy expenditure was reduced in high-fat-fed ATGLKO mice
(Figure 5E), as previously reported (Hoy et al., 2011). Interest-
ingly, CGI-58 knockdown did not increase energy expenditure
in ATGLKO mice (Figure 5E). Collectively, these data suggest
that CGI-58 and ATGL regulate HFD-induced obesity and energy
balance via distinct mechanisms.(CGI-58D, ATGLKO/CGI-58D) in conjunction with high-fat diet feeding for
6 weeks.
(A) Carboxylesterase (Ces1g/Es-X and Ces1d/TGH) protein expression in
whole liver was determined by western blotting, with Ces1g or Ces1d
knockout mouse liver used as genetic controls.
(B andC) Densitometric analysis of hepatic carboxylesterase (Ces1g/Es-X and
Ces1d/TGH) protein expression.
(D) qPCR quantification of hepatic Ces1g/Es-X.
(E) qPCR quantification of hepatic Ces1d/TGH.
For (F)–(I), male C57BL/6Nmice weremaintained on a chow diet in conjunction
with biweekly injections (25 mg/kg) of either control ASO or CGI-58 ASO for
3 weeks. During the third week of ASO treatment, the mice were orally gav-
aged daily with either vehicle (VEH) or 50 mg/kg body weight of the exogenous
PPARa agonist WY-14643 (WY).
(F) qPCR quantification of the PPARa target gene Cyp4a10 in mouse liver.
(G) Hepatic triacylglycerol (TAG) levels.
(H) qPCR quantification of hepatic Ces1g/Es-X.
(I) qPCR quantification of hepatic Ces1d/TGH
Data represent the mean + SEM of three to five mice per group; and values not
sharing a common superscript differ significantly (p < 0.05).
Figure 4. CGI-58 Knockdown Limits ATGL-
Mediated Lipolysis in White Adipose Tissue
At 4–6 weeks of age, male wild-type or ATGLKO
mice were treated with either a non-targeting
control ASO (WT, ATGLKO) or an ASO targeting
CGI-58 (CGI-58D, ATGLKO/CGI-58D) in conjunc-
tion with high-fat diet feeding for 6 weeks.
(A) RelativemRNA expression of CGI-58 and ATGL
in whole epididymal WAT.
(B) Total TAG hydrolase activity in cytosolic ex-
tracts of whole epididymal WAT.
(C) Fedmice were treated with either saline vehicle
or CL316243 agonist (0.1 mg/g body weight) to
stimulate lipolysis, and plasma glycerol and NEFA
were measured after 15 min.
(D) Surgically dissected epididymal WAT explants
were incubated in basal media (basal) or media
supplemented with 100 mM isoproterenol (stimu-
lated) for 4 hr.
Data represent the mean + SEM from four to seven
mice per group, and values not sharing a common
superscript differ significantly (p < 0.05).ATGL Deficiency Promotes Brown Adipose Tissue Lipid
Storage, but CGI-58 ASO-Treatment Does Not
Given the differential phenotypes seen in energy expenditure,
we also examined alterations in brown adipose tissue (BAT)
function in single- and double-deficient mice. One potential
limitation to note is that CGI-58 was only partially suppressed
by ASO treatment in BAT, where CGI-58 ASO treatment
reduced CGI-58 protein expression by 60% in both WT
and ATGLKO mice (Figures 6A and 6B). In agreement with find-
ings in liver (Figures 2B and 2C) and WAT (Figure 5F), ATGLKO
mice had marked reductions in the expression of enzymes
involved in de novo lipogenesis, yet CGI-58 ASO treatment
did not result in similar repression of lipogenesis (Figure 6A).
As has been previously shown (Haemmerle et al., 2006,
2011; Schreiber et al., 2015; Ahmadian et al., 2011), ATGL
deficiency significantly increases sub-scapular BAT weight
(Figure 6C), which is accompanied by marked brown adipo-
cyte hypertrophy and enhanced lipid droplet size (Figure 6E).
In contrast, CGI-58 knockdown had no effect on BAT weight
or brown adipocyte hypertrophy, either in the presence or
absence of ATGL (Figures 6C and 6E). Interestingly, ATGLKO
mice also had significantly increased expression of macro-
phage markers (F4/80 and CD11c), but this was not seen
with CGI-58 ASO treatment (Figure 6D). These data suggestCquite different roles for ATGL and
CGI-58 in BAT inflammation and lipid
metabolism.
Single and Double CGI-58 or ATGL
Loss of Function Results in Marked
Improvements in Glucose
Tolerance
It has previously been reported that
CGI-58 ASO treatment (Brown et al.,
2010; Lord et al., 2012; Cantley et al.,
2013) and global deficiency of ATGL(Haemmerle et al., 2006) paradoxically result in improvements
in glucose tolerance, despite both models exhibiting marked he-
patic steatosis. In agreement, we show that CGI-58 or ATGL loss
of function alone results in marked improvements in systemic
glucose tolerance, (Figure 7). Despite striking hepatic steatosis
in ATGLKO/CGI-58D mice, glucose clearance was similar to
ATGLKO mice (Figure 7). These data confirm previous reports
(Haemmerle et al., 2006; Kienesberger et al., 2009; Brown
et al., 2010; Lord et al., 2012; Cantley et al., 2013) that hepatic
TAG accumulation can be dissociated from diminished glucose
tolerance. However, CGI-58 and ATGL likely regulate glucose
tolerance through distinct mechanisms (Cantley et al., 2013; Kie-
nesberger et al., 2009), as discussed in detail below.
DISCUSSION
Although it has become generally accepted that CGI-58 regu-
lates TAG hydrolysis by co-activating ATGL, results from this
study suggest that CGI-58 can regulate TAGmetabolism and he-
patic inflammation via mechanisms that do not involve ATGL.
Themajor findings of theses studies are that (1) CGI-58 regulates
hepatic TAG storage through an ATGL-independentmechanism;
(2) ATGL and CGI-58 reciprocally regulate hepatic DAG levels;
(3) ATGL deficiency, but not CGI-58 loss of function, results inell Reports 16, 939–949, July 26, 2016 943
Figure 5. Single CGI-58 or ATGL Deficiency
Prevents High-Fat-Diet-Induced Obesity via
Distinct Mechanisms
At 4–6 weeks of age, male wild-type or ATGLKO
mice were treated with either a non-targeting con-
trol ASO (WT, ATGLKO) or an ASO targeting CGI-58
(CGI-58D, ATGLKO/CGI-58D) in conjunction with
either chow or high-fat diet feeding for 6 weeks.
(A) Body weight of WT and ATGLKO mice fed chow
diet and treated with control ASO (n = 5 mice per
group).
(B) Body weight of mice fed high-fat diet (n = 20–25
mice per group).
(C) Epididymal fat pad weight after 6 weeks of
high-fat diet (n = 8–10 mice per group).
(D) Adipocyte cross-sectional area after 6 weeks of
high-fat diet was measured in epididymal WAT
sections from five individual mice per group and a
total of 500–550 adipocytes per group.
(E) Following 2–3 weeks of treatment and high-fat
diet, oxygen consumption (VO2) was measured
over a 24-hr period, n = 4–5 mice per group; *p <
0.05 WT versus CGI-58D, #p < 0.05 WT versus
ATGLKO, $p < 0.05 WT versus ATGLKO/CGI-58D.
(F) Lipogenic gene expression in epididymal WAT
was measured by qPCR (n = 5 per group).
(G) Lipase gene expression in epididymal WAT
was measured by qPCR (n = 5 per group).
Abbreviations: Aadac, arylacetamide deacetylase;
Ces1g, carboxylesterase 1g (also known as Es-X);
Ces1d, carboxylesterase 1d (also known as TGH);
Dgat2, diacylglycerol acyltransferase 2; Fas, fatty
acid synthase; Hsl, hormone-sensitive lipase;
Pparg2, peroxisome proliferator-activated recep-
tor g; SREBP1c, sterol regulatory element-binding
protein 1c. Data represent the mean + SEM, and
values not sharing a common superscript differ
significantly (p < 0.05).suppression of lipogenic enzyme expression in liver, WAT, and
BAT; 4) the hepatic expression of key TAG lipases (Ces1g/Es-X
and Ces1d/TGH) are reduced in CGI-58 and ATGL loss-of-func-
tion mouse models; (5) provision of an exogenous PPARa
agonist can reverse CGI-58 ASO-driven hepatic steatosis and
altered lipase expression; (6) CGI-58 knockdown in WAT limits
ATGL-mediated lipolysis, supporting a co-activation model; (7)
ATGL deficiency promotes BAT lipid storage, but CGI-58 ASO
treatment does not; (8) single CGI-58 or ATGL deficiency simi-
larly protects against HFD-induced obesity via increased energy
expenditure or reduced de novo lipogenesis, respectively; and
(9) single and double CGI-58 or ATGL loss of function results in
marked improvements in glucose tolerance, despite severe he-
patic lipotoxicity. Collectively, this work supports distinct roles
for ATGL and CGI-58 in hepatic and adipose tissue lipid meta-
bolism, insulin action, and inflammation. In NLSD patients, fatty
liver disease and hepatomegaly occur more frequently with CGI-
58 mutations than with ATGL mutations (Lord and Brown, 2012),
suggesting that CGI-58 has an ATGL-independent function in
the liver. However, single CGI-58 or ATGL deficiency in mice ap-
pears to increase hepatic TAG levels to a similar extent (Fig-
ure 1E), and no previous studies have directly tested whether
CGI-58 is a specific co-activator of ATGL in the liver. We found
that maximal ATGL hydrolase activity in the liver required co-944 Cell Reports 16, 939–949, July 26, 2016activation by endogenous CGI-58 (Figure 1C). Likewise, CGI-
58 knockdown did not further decrease hydrolase activity in
ATGL deficient livers (Figure 1C), suggesting that CGI-58 does
not co-activate other hepatic TAG hydrolases. Since hepatic
TAG levels did not correlate with hydrolase activity in CGI-58
knockdown mice, a distinct pathway must account for TAG
accumulation.
Although these results clearly demonstrate the existence of
a function of CGI-58 distinct from the co-activation of ATGL,
the ATGL-independent mechanism by which CGI-58 regulates
TAG metabolism and inflammation remains unknown. CGI-58
has previously been reported to possess lysophosphatidic acid
acyltransferase (LPAAT) activity (Ghosh et al., 2008; Montero-
Moran et al., 2010), suggesting a potential role in lipid synthesis
or signaling. However, subsequent investigation has revealed
that the LPAAT activity originally associated with recombinant
CGI-58 (Ghosh et al., 2008; Montero-Moran et al., 2010) was
due to a bacterial contaminant acquired during the affinity
purification process (McMahon et al., 2014). This was initially
suggested by the fact that mutations of the predicted acyl-
transferase active site of CGI-58 did not reduce LPAAT activity
(McMahon et al., 2014). More importantly, affinity purification
of recombinant CGI-58 from a bacterial strain that lack the sole
LPAAT found in the Escherichia coli genome (plsC) yielded no
Figure 6. ATGL Deficiency, but Not CGI-58
Knockdown, Promotes Brown Adipocyte
Hypertrophy and Suppresses Lipogenic
Protein Expression
At 4–6 weeks of age, male wild-type or ATGLKO
mice were treated with either a non-targeting
control ASO (WT, ATGLKO) or an ASO targeting
CGI-58 (CGI-58D, ATGLKO/CGI-58D) in conjunc-
tion with high-fat diet feeding for 6 weeks.
(A) Western blot analysis of brown adipose
tissue (BAT).
(B) Densitometric quantification of CGI-58 protein
expression.
(C) Interscapular fat pad weight normalized to
tibia length.
(D) Relative gene expression in whole inter-
scapular BAT.
(E) Representative H&E-stained BAT sections;
scale bar represents 75 mm.
Data represent mean + SEM of n = 5–9 mice per
group, and values not sharing a common super-
script letter differ significantly (p < 0.05). *p < 0.05
versus WT.
Abbreviations: ACC1, acetyl-coenzyme A (acetyl-
CoA) carboxylase 1; AceCS1, acetyl-CoA synthe-
tase 1; ATGL, adipose triglyceride lipase; ATP-CL,
ATP-citrate lyase; FAS, fatty acid synthase.detectable LPAAT activity (McMahon et al., 2014). It is important
to note that other proteins have been mistakenly identified as
LPAAT enzymes due to similar problemswith affinity co-purifica-
tion of bacterial LPAATs (Gallop et al., 2005). It is now clear that
the ATGL-independent function of CGI-58 does not stem from
intrinsic acyltransferase activity but instead involves a separateCactivity of CGI-58 that requires further
investigation. In the continued search for
an ATGL-independent mechanism for
CGI-58 it is important to consider early
studies in human skin fibroblasts with
mutations in CGI-58 (Igal and Coleman,
1996, 1998). These studies identified a
primary defect in the recycling of TAG-
derived acylglycerols into phospholipids,
rather than defective TAG hydrolysis
per se (Igal and Coleman, 1996, 1998).
Although lipase activity was not defective
in NLSD skin fibroblasts (Igal and Cole-
man, 1996), it is important to point out
that multiple CGI-58 mutations cause
NLSD (Lord and Brown, 2012). Some
CGI-58mutations could exclusively affect
either ATGL co-activation or ATGL-inde-
pendent functions. In contrast, CGI-58
knockdown in mice abolishes all func-
tions of CGI-58, and we have demon-
strated that CGI-58 knockdown does
indeed decrease ATGL activity in liver
(Figure 1C).
One unexpected finding that may
shed light into how CGI-58 regulatesTAG metabolism in the liver is that CGI-58 knockdown results
in reorganization of hepatic lipase expression (Figure 3). Our
studies show that the hepatic expression of several key TAG li-
pases (Ces1g/Es-X, Ces1d/TGH) was reduced in CGI-58 and
ATGL loss-of-function mice (Figure 3). Our data also support a
model whereby the reduced expression of Ces1g/Es-X andell Reports 16, 939–949, July 26, 2016 945
Figure 7. Either CGI-58 or ATGL Loss of
Function Improves Glucose Tolerance
At 4–6 weeks of age, male wild-type or ATGLKO
mice were treated with either a non-targeting
control ASO (WT, ATGLKO) or an ASO targeting
CGI-58 (CGI-58D, ATGLKO/CGI-58D) in conjunction
with either chow or high-fat diet feeding for
4–5 weeks.
(A) Glucose tolerance test curves.
(B) Area under the curve (AUC) analysis for glucose
tolerance test (GTT).
Data represent the mean + SEM n = 5–9 per group,
and values not sharing a common superscript
differ significantly (p < 0.05).Ces1d/TGH likely involves reduced PPARa activity in the liver of
CGI-58 ASO-treated mice (Figures 3H and 3I). Provocatively,
these findings indicate that secondary changes in other TAG li-
pases may in part contribute to the hepatic steatosis seen in
CGI-58 and ATGL loss-of-function mice. Although both Ces1d
and Ces1g have TAG hydrolase activity, mice lacking these
TAG hydrolases have very different metabolic phenotypes (Quir-
oga et al., 2012; Wei et al., 2010; Lian et al., 2012). Ces1d
knockout mice present with decreased lipogenesis, increased
fatty acid oxidation and resistance to HFD-induced hepatic stea-
tosis (Wei et al., 2010; Lian et al., 2012). In contrast, Ces1g
knockout mice fed chow diet present with increased lipogenesis
and insulin resistance (Quiroga et al., 2012). Collectively, our
studies demonstrate that complex alterations in both lipase (Fig-
ure 3) and lipogenic (Figures 2B, 2C, 5F, and 6A) gene expression
may in part contribute to altered TAG accumulation in CGI-58
and ATGL loss-of-function mice.
Given the product of TAG hydrolysis is DAG, it is important to
consider the shared and divergent effects of ATGL and CGI-58
on hepatic DAG metabolism. First, CGI-58 knockdown in mice
leads to increased hepatic DAG levels (Brown et al., 2010; Cant-
ley et al., 2013) and prevents the inflammatory cytokine-driven
generation of several signaling lipids that can be derived from
DAG (Lord et al., 2012). Two recent reports also support the pos-
sibility that CGI-58 could play a direct role in the regulation of
DAG localization or utilization. First, CGI-58 knockdown causes
hepatic DAG accumulation in lipid droplets and endoplasmic re-
ticulum while preventing accumulation of DAG at the plasma
membrane (Cantley et al., 2013). Second, CGI-58 co-activation
broadens the selectivity of ATGL for the sn-2 position of TAG
to include the sn-1 position, resulting in the generation of both
sn-1,3 and sn-2,3 DAG (Eichmann et al., 2012). Interestingly,
we show here that ATGL deficiency decreases hepatic DAG
levels compared to control mice, whereas CGI-58 knockdown
increases hepatic DAG both in the presence or absence of
ATGL (Figure 1F). Although the mechanism by which CGI-58
knockdown causes DAG accumulation within the lipid droplet
and endoplasmic reticulum compartment is unknown, the recip-
rocal reduction in hepatic DAG by ATGL deficiency likely directly
stems from defective TAG to DAG conversion in hepatocytes. In
support of this concept, adipocyte-specific deletion of ATGL946 Cell Reports 16, 939–949, July 26, 2016likewise reduces total adipose DAG levels (Ahmadian et al.,
2011). Given that ATGL and CGI-58 reciprocally regulate hepatic
DAG levels, and the fact that CGI-58 knockdown increases he-
patic DAG in both the presence and absence of ATGL (Figure 1F),
it is tempting to speculate that CGI-58 plays an ATGL-indepen-
dent role in DAG shuttling or metabolism.
Undoubtedly, there is strong evidence that CGI-58 co-acti-
vates ATGL in certain tissues to promote TAG hydrolysis (Lass
et al., 2006; Granneman et al., 2007, 2009; Schweiger et al.,
2008; Yang et al., 2013; Cornaciu et al., 2011; Wang et al.,
2011; MacPherson et al., 2013; Zierler et al., 2013). However,
results from this study indicate that CGI-58 can suppress hepatic
inflammatory responses in vivo via a mechanism not involving
ATGL. In fact, there is a clear distinction between ATGL and
CGI-58 in their ability to impact systemic inflammatory re-
sponses and the progression of simple fatty liver to steatohe-
patitis or fibrosis. In agreement with the data presented here,
hepatocyte-specific CGI-58 deficiency promotes marked fatty
liver which progresses into steatohepatitis and fibrosis with
age (Guo et al., 2013). In contrast, hepatocyte-specific ATGL
deficiency results in a mild fatty liver phenotype, which does
not progress to steatohepatitis or fibrosis, even after one year
(Wu et al., 2011). When challenged acutely with lipopolysaccha-
ride (LPS), mice lacking ATGL or CGI-58 in the liver respond quite
differently (Lord et al., 2012; Jha et al., 2014). While both ATGL
and CGI-58 loss-of-function models have increased levels of
circulating TH1 cytokines when challenged with LPS, the tissue
source of these cytokines seems to be quite different (Lord
et al., 2012; Jha et al., 2014). In this case, ATGL deficient mice
have elevated LPS-induced cytokine gene expression in the liver
(Jha et al., 2014), whereas CGI-58 ASO-treated mice have blunt-
ed LPS-induced cytokine gene expression in the liver (Lord et al.,
2012). In the case of CGI-58 ASO-treated mice, it seems that the
major source of elevated circulating TH1 cytokines is from white
adipose tissue (WAT) (Lord et al., 2012). A major contributing
factor to differences in acute inflammatory responses between
ATGL and CGI-58 is the divergent role these proteins play in
macrophage function (Miao et al., 2014; Chandak et al.,
2010; Aflaki et al., 2011a, 2011b). Macrophage-selective defi-
ciency of ATGL skews macrophages toward the M2-like pheno-
type without altering inflammasome activation (Chandak et al.,
2010; Aflaki et al., 2011a, 2011b). In contrast, macrophage-spe-
cific deletion of CGI-58 causes macrophages to acquire an M1-
like phenotype and results in reactive-oxygen-species-driven
activation of the NLRP3 inflammasome (Miao et al., 2014).
Therefore, much like data shown here in mouse liver, the roles
of CGI-58 and ATGL in macrophages are likely independent of
one another.
Even though ATGL or CGI-58 loss of function causes ectopic
TAGaccumulation inmultiple tissues, it has historically been par-
adoxical why this is not associated with systemic insulin resis-
tance (Haemmerle et al., 2006; Brown et al., 2010; Lord et al.,
2012; Cantley et al., 2013). In agreement with previous studies
(Haemmerle et al., 2006; Brown et al., 2010; Lord et al., 2012;
Cantley et al., 2013), we show here that CGI-58 ASO treatment
alone improves glucose tolerance to a similar degree seen in
ATGL global knockout mice (Figure 7). Although both of these
mouse models of defective TAG hydrolysis exhibit a similar
improvement in glucose tolerance, the mechanisms underlying
these improvements likely stem from different sources. In the
case of CGI-58, it has previously been shown that despite large
accumulation of hepatic DAG in CGI-58 ASO-treated mice, they
are protected from DAG-induced insulin resistance due to
sequestration of hepatic DAGs in the lipid droplet and endo-
plasmic reticulum (Cantley et al., 2013). This sequestration of
DAGs within hepatocytes results in prevention of HFD-induced
accumulation of DAGs at the plasmamembrane, where they nor-
mally act to negatively regulate insulin receptor-driven signaling
events (Perry et al., 2014). Collectively, the improvements in
glucose tolerance seen in CGI-58 ASO-treatedmice stem almost
exclusively from improvements in hepatic insulin action via a
mechanism involving DAG sequestration (Cantley et al., 2013).
In contrast, the improvements in glucose tolerance in global
ATGL knockout mice have been linked to improvements in
skeletal muscle insulin action and improved insulin-stimulated
glucose uptake (Kienesberger et al., 2009; Sitnick et al., 2013).
Therefore, the striking improvements in glucose tolerance seen
with either ATGL or CGI-58 deficiency derive from skeletal mus-
cle-specific or liver-specific improvements in insulin signaling,
respectively (Brown et al., 2010; Lord et al., 2012; Cantley
et al., 2013; Kienesberger et al., 2009; Sitnick et al., 2013).
In conclusion, these studies clearly demonstrate the existence
of biochemical functions for CGI-58 that does not rely on ATGL
co-activation in mouse liver. While CGI-58 can indeed directly
interact to co-activate ATGL-mediated TAG hydrolysis (Lass
et al., 2006; Granneman et al., 2007, 2009; Schweiger et al.,
2008; Yang et al., 2013; Cornaciu et al., 2011; Wang et al.,
2011; MacPherson et al., 2013; Zierler et al., 2013), this mecha-
nism is likely only relevant in certain cellular contexts. The ATGL
co-activation mechanism undoubtedly occurs in adipocytes
(Lass et al., 2006; Granneman et al., 2007, 2009; Schweiger
et al., 2008; Yang et al., 2013; Cornaciu et al., 2011; Wang et al.,
2011;MacPherson et al., 2013; Zierler et al., 2013), but the elusive
ATGL-independent function of CGI-58 predominates in many
other cell types to regulate both TAG metabolism and inflamma-
tion. Moving forward, it is critical to make the distinction that
molecular mechanisms regulating catecholamine-stimulated
lipolysis in adipocytes may be quite different than mechanisms
driving lipolysis in non-adipocytes. Future studies to understandthe ATGL-independent function(s) of CGI-58 in the liver could
lead to future therapies for NLSD, non-alcoholic fatty liver dis-
ease, and more advanced forms of end-stage liver disease.
EXPERIMENTAL PROCEDURES
Animal Studies
Global ATGLKO mice were previously generated on a mixed background
(Haemmerle et al., 2006) and subsequently backcrossed onto a C57BL/6N
background more than ten generations (Kienesberger et al., 2009). Breeding
was performed as previously described (Kienesberger et al., 2009).
At 4–6 weeks of age, male WT and ATGLKO mice were subjected to HFD
feeding (45% energy as fat from lard) and biweekly intraperitoneal injections
(25 mg/kg) of either a non-targeting second-generation control ASO or a sec-
ond-generation ASO specifically targeting CGI-58 as previously described
(Brown et al., 2010). For studies examining PPARa signaling, 6-week-old
male C57BL6 mice were injected with control or CGI-58 ASOs and maintained
on a standard chow diet for a period of 3 weeks to achieve adequate knock-
down. During the last week of ASO injection (week 3),micewere orally gavaged
with either vehicle (1.0% carboxymethylcellulose [CMC] and 0.1% Tween 80)
or WY-14643 (50 mg/kg per day) once daily for 7 days. All mice were strictly
necropsied between 9:00 and 10:00 a.m. Biochemical assays for glucose,
non-esterified fatty acids, and glycerol have been previously described (Brown
et al., 2010; Lord et al., 2012; Cantley et al., 2013). All experimental procedures
were approved by the Institutional Animal Care and Use Committee at Wake
Forest University School of Medicine or the Cleveland Clinic.
TAG Hydrolase Assays
Total TAG hydrolase activity was measured as previously described
(Schweiger et al., 2014) in frozen liver from mice fasted for 4 hr.
Liver Lipid Analyses
Liver TAG and DAG levels were extracted and measured as previously
described (Brown et al., 2010; Lord et al., 2012; Cantley et al., 2013).
Histological Analysis
H&E staining of paraffin-embedded liver sections was performed as previously
described (Brown et al., 2010).
RNA and Protein Methods
Tissue RNA extraction and real-time PCR were conducted as previously
described (Brown et al., 2010; Lord et al., 2012) using the Applied Biosystems
7500 Real-Time PCR System. Primer information is available upon request.
For western blotting, whole-tissue homogenates were made from multiple
tissues in a modified radioimmunoprecipitation assay buffer, as previously
described (Brown et al., 2010; Lord et al., 2012). Proteins were separated by
4%–12% SDS-PAGE and transferred to polyvinylidene difluoride membranes,
and proteins were detected after incubation with specific antibodies, for which
detailed information is available upon request.
Glucose Tolerance Testing
Glucose tolerance was measured as previously described (Brown et al., 2010;
Lord et al., 2012; Cantley et al., 2013) in male mice following 4–7 weeks of HFD
and ASO treatment.
Indirect Calorimetry and Metabolic Cage Measurements
Weight matched mice were acclimated to metabolic cages for 48 hr and on
day 2 were injected with ASO. Thereafter, physical activity, oxygen consump-
tion (VO2), carbon dioxide production (VCO2), and respiratory exchange ratio
(RER) were continually monitored for an additional 48 hr using the Oxymax
CLAMS system (Columbus Instruments) at a temperature of 22C. Data repre-
sent the last 6 a.m. to 6 a.m. period after adequate acclimation.
Statistical Analysis
Data are expressed as themean ± SEM. All data were analyzed using two-way
ANOVA followed by Student’s t tests for post hoc analysis. Differences wereCell Reports 16, 939–949, July 26, 2016 947
considered significant at p < 0.05. All analyses were performed using JMP
version 5.0.12 (SAS Institute) software.
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